| | Identification | Back Directory |  | [Name] 
 CH-275
 |  | [CAS] 
 174688-78-9
 |  | [Synonyms] 
 CH-275
 CYS-LYS-PHE-PHE-D-TRP-IAMP-THR-PHE-THR-SER-CYS
 [DES-ALA1, DES-GLY2, DES-ASN5, D-TRP8, IAMP9]SOMATOSTATIN-14
 Cys-Lys-Phe-Phe-D-Trp-IAMp-Thr-Phe-Thr-Ser-Cys (Disulfide bridge Cys3-Cys14)
 |  | [Molecular Formula] 
 C74H96N14O15S2
 |  | [MDL Number] 
 MFCD02264518
 |  | [MOL File] 
 174688-78-9.mol
 |  | [Molecular Weight] 
 1485.79
 | 
 | Chemical Properties | Back Directory |  | [Boiling point ] 
 1732.9±65.0 °C(Predicted)
 |  | [density ] 
 1.235±0.06 g/cm3(Predicted)
 |  | [storage temp. ] 
 Store at -20°C
 |  | [form ] 
 Powder
 |  | [pka] 
 2.93±0.70(Predicted)
 |  | [color ] 
 White to off-white
 |  | [Water Solubility ] 
 Soluble to 0.30 mg/ml in water
 |  | [Sequence] 
 Cys-Lys-Phe-Phe-{d-Trp}-Phe-Thr-Phe-Thr-Ser-Cys (Modifications: Cyclic Cys1-Cys11, X=4-[[(1-methylethyl)amino]methyl]-Phe)
 | 
 | Hazard Information | Back Directory |  | [Uses] 
 CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst1) with a Ki of 52 nM[1]. CH 275 acts as a potent and selective sst1?agonist (IC50=30.9 nM) and also displays?IC50?values of 345 nM, >1?μM, >10?μM, >10?μM for human sst3, sst4, sst2?and sst5,?respectively[2]. CH 275 can be used for the research of alzheimer’s disease[3].
 |  | [in vivo] 
 
 CH275 (osmotic pump administration; 56 μM; two weeks) decreases the?level of neprilysin/SRIF in the?App?knock-in mice[3].CH275 directly injects into the Lacunosum molecular layer (Lmol) layer of 2-month-old AppNL-G-F mice for four months. AppNL-G-F mice begin to exhibit Aβ plaques at two months of age, but CH275 leads to robustly increased the expression of neprilysin in hippocampus which is paralleled by a clear reduction in Aβ plaque load in the same region, and without causing any toxic side effects[3]. |  | [IC 50] 
 SSTR1
 |  | [References] 
 [1] L Chen, et al. Structural basis for the binding specificity of a SSTR1-selective analog of somatostatin. Biochem Biophys Res Commun. 1999 May 19;258(3):689-94. DOI:10.1006/bbrc.1999.0699
 [2] J E Rivier, et al. Potent somatostatin undecapeptide agonists selective for somatostatin receptor 1 (sst1). J Med Chem. 2001 Jun 21;44(13):2238-46. DOI:10.1021/jm010037+
 [3] Per?Nilsson,?et al. Somatostatin receptor subtypes 1 and 4 redundantly regulate neprilysin, the major amyloid β-degrading enzyme, in brain.
 | 
 | 
                    
                        
                            | Company Name: | BOC Sciences |  
                            | Tel: | 1-631-485-4226; 16314854226 |  
                            | Website: | https://www.bocsci.com |  |